| [1] |
Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets[J]. Physiol Rev, 2007, 87 (3): 905-31.
|
| [2] |
Klinge CM. Estrogen receptor interaction with estrogen response elements[J]. Nucleic Acids Res 2001, 29(14): 2905-19.
|
| [3] |
Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy[J]. Nat Rev Cancer, 2011, 11(8): 59 7-608.
|
| [4] |
Wang Z, Zhang X, Shen P, et al. Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66[J]. Biochem Biophys Res Commun, 20 05, 336(4): 1023-7.
|
| [5] |
Wang Z, Zhang X, Shen P, et al. A variant of estrogen receptor-α, hER-α36: transduction of estrogen-and antiestrogen-dependent membrane-initiated mitogenic signaling[J]. Proc Nat Acad Sci U S A, 2006, 103(24): 9063-8.
|
| [6] |
Lee LM, Cao J, Deng H, et al. ER-alpha36, a novel variant of ERalpha, is expressed in ER-positive and -negative human breast carcinomas [J]. Anticancer Res, 2008, 28(1B): 479-83.
|
| [7] |
Lin SL, Yan LY, Zhang XT, et al. ER-alpha36, a variant of ERalpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways[J]. PLoS One, 20 10, 5(2): e9013.
|
| [8] |
Wang J, Li J, Fang R, et al. Expression of ERalpha36 in gastric cancer samples and their matched normal tissues[J]. Oncol Lett, 20 12, 3(1): 172-5.
|
| [9] |
Miceli V, Cocciadiferro L, Fregapane M, et al. Expression of wildtype and variant estrogen receptor alpha in liver carcinogenesis and tumor progression[J]. Omics, 2011, 15(5): 313-7.
|
| [10] |
Marquez DC, Pietras RJ. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells [J]. Oncogene, 2001, 20(39): 5420-30.
|
| [11] |
Kang L, Zhang X, Xie Y, et al. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling[J]. Molecular Endocrinology (Baltimore, Md), 2010, 24 (4): 709-21.
|
| [12] |
Tong JS, Zhang QH, Wang ZB, et al. ER-alpha36, a novel variant of ER-alpha, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCdelta/ERK pathway[J]. PLoS One, 2010, 5(11): e15408.
|
| [13] |
Zou Y, Ding L, Coleman M, et al. Estrogen receptor-alpha (ERalpha) suppresses expression of its variant ER-alpha 36[J]. FEBS Lett, 2009, 583(8): 1368-74.
|
| [14] |
Li G, Zhang J, Jin K, et al. Estrogen receptor-alpha36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells[J]. Mol Oncol, 20 13, 7(3): 611-24.
|
| [15] |
Tu BB, Lin SL, Yan LY, et al. ER-alpha36, a novel variant of estrogen receptor alpha, is involved in EGFR-related carcinogenesis in endometrial cancer[J]. Am J Obstet Gynecol, 20 11, 205(3): 227. e1-6.
|
| [16] |
Zhang XT, Kang LG, Ding L, et al. A positive feedback loop ofER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells[J]. Oncogene, 2011, 30(7): 770-80.
|
| [17] |
Kang L, Guo Y, Zhang X, et al. A positive cross-regulation of HER2 and ER-alpha36 controls ALDH1 positive breast cancer cells[J]. J Steroid Biochem Mol Biol, 2011, 127(3-5): 262-8.
|
| [18] |
Zhao Y, Deng C, Lu W, et al. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer[J]. Mol Med, 2011, 17(11-12): 1233-41.
|
| [19] |
Zhang J, Li G, Li Z, et al. Estrogen-independent effects of ERalpha36 in ER-negative breast cancer[J]. Steroids, 2012, 77(6): 66 6-73.
|
| [20] |
Pelekanou V, Notas G, Kampa M, et al. ERalpha36, a new variant of the ERalpha is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines[J]. Steroids, 2012, 77(10): 928-34.
|
| [21] |
Shi L, Dong B, Li Z, et al. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer[J]. J Clin Oncol, 2009, 27(21): 3423-9.
|
| [22] |
Vranic S, Gatalica Z, Deng H, et al. ER-alpha36, a novel isoform of ER-alpha66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast[J]. J Clin Pathol, 2011, 64 (1): 54-7.
|
| [23] |
Zhang X, Ding L, Kang L, et al. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells[J]. PLoS One, 2012, 7(1): e30174.
|
| [24] |
Zhang X T, Ding L, Kang LG, et al. Involvement of ER-alpha36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ERnegative breast cancer cells[J]. Oncol Rep, 2012, 27(6): 2057-65.
|
| [25] |
Chaudhri RA, Olivares-Navarrete R, Cuenca N, et al. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-alpha36 (ERalpha36)[J]. J Biol Chem, 2012, 287(10): 7169-81.
|
| [26] |
Zhang CC, Shapiro DJ. Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis[J]. J Biol Chem, 20 00, 275(1): 479-86.
|
| [27] |
Deng H, Zhang X T, Wang M L, et al. ER-alpha36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells[J]. PLoS One, 2014, 9(2): e88034.
|
| [28] |
Liu WG, Zhang QX, Wang YL, et al. Over-expression of estrogen receptor-alpha 36 promotes the invasion and metastasis ability of human breast cancer cell MCF-7[J]. Ji Chu Yi Xue Yu Lin Chuang, 2013, 33(6): 713-7. [刘旺根, 张钦宪, 王云龙, 等. ER-α36过表达促进人乳腺癌MCF-7细胞侵袭转移能力[J]. 基 础医学与临床, 2013, 33(6): 713-7.]
|
| [29] |
Yu L, Ke W, Wang Y, et al. Predictive and prognostic value of ER-alpha36 expression in breast cancer patients treated with chemotherapy[J]. Steroids, 2014, 84:11-6.
|
| [30] |
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-16.
|
| [31] |
Jordan VC. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer[J]. Endocr Relat Cancer, 2014, 21(3): R235-46.
|
| [32] |
Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance[J]. Nat Rev Cancer, 2002, 2( 2): 101-12.
|
| [33] |
Zhang X, Wang ZY. Estrogen receptor-alpha variant, ERalpha36, is involved in tamoxifen resistance and estrogen hypersensitivity[J]. Endocrinology, 2013, 154(6): 1990-8.
|
| [34] |
Yin L, Zhang XT, Bian X W, et al. Disruption of the ER-alpha36- EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells[J]. PLoS One, 2014, 9(9): e107369.
|
下载:
